CITADEL Trial-in-Progress Presented at ESMO 2024

Molly Li, MBBS, of the Chinese University of Hong Kong, discusses the abstract on the CITADEL trial-in-progress presented at the European Society of Clinical Oncology (ESMO) 2024 Congress.

The CITADEL trial, which is evaluating combining immunotherapy with Trop2 antibody-drug conjugates in early-stage non-small cell lung cancer (NSCLC), is an investigator-initiated, open-label, single arm, multicenter phase II study investigating the efficacy of perioperative pembrolizumab plus sacituzumab govitecan in patients with resectable stage II-III NSCLC without EGFR/ALK alterations.

“This study is currently actively enrolling, and we feel that the enrollment will continue through around 2025 and will end at around the end of next year, so looking forward to the enrollment, as well as the results so far,” Dr. Li said.

Eligible patients will receive four cycles of neoadjuvant pembrolizumab 200 mg every three weeks and sacituzumab govitecan 10 mg/kg on days one and eight every three weeks. Patients will undergo surgical resection 4 to 8 weeks after the fourth cycle of study treatment. The primary endpoint of the study is the pathological complete response rate.

“We hypothesize that this perioperative pembrolizumab plus sacituzumab govitecan will offer a better pathological complete response rate compared to the current standard of care, perioperative pembrolizumab plus chemotherapy,” Dr. Li said.